Aspirin Use Is Associated With Improved Outcomes in Inflammatory Breast Cancer Patients

Christopher Johns; Allen Yen; Asal Rahimi; Yu-Lun Liu; Ann Marilyn Leitch; Ann Spangler; Prasanna Alluri; Chika Nwachukwu; Rachel Wooldridge; Deborah Farr; D. W. Nathan Kim

doi:10.4048/jbc.2023.26.e3

추천

검색

자료유형: 학술저널

저자정보: Christopher Johns (Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas USA.) Allen Yen (Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas USA.) Asal Rahimi (Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas USA.) Yu-Lun Liu (Department of Population and Data Sciences University of Texas Southwestern Medical Center Dallas USA.) Ann Marilyn Leitch (Department of Surgical Oncology University of Texas Southwestern Medical Center Dallas USA.) Ann Spangler (Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas USA.) Prasanna Alluri (Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas USA.) Chika Nwachukwu (Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas USA.) Rachel Wooldridge (Department of Surgical Oncology University of Texas Southwestern Medical Center Dallas USA.) Deborah Farr (Department of Surgical Oncology University of Texas Southwestern Medical Center Dallas USA.) D. W. Nathan Kim (Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas USA.)

저널정보: 한국유방암학회 Journal of Breast Cancer Journal of Breast Cancer Vol.26 No.1

발행연도: 2023.2

수록면: 14 - 24 (11page)

DOI: 10.4048/jbc.2023.26.e3

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Purpose: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer and has a high propensity for distant metastases. Our previous data suggested that aspirin (acetylsalicylic acid, ASA) use may be associated with reduced risk of distant metastases in aggressive breast cancer; however, there are no reported studies on the potential benefit of ASA use in patients with IBC. Methods: Data from patients with non-metastatic IBC treated between 2000–2017 at two institutions, were reviewed. Overall survival (OS), disease-free survival (DFS), and distant metastasis-free survival (DMFS) were performed using Kaplan-Meier analysis. Univariate and multivariable logistic regression models were used to identify significant associated factors. Results: Of 59 patients meeting the criteria for analysis and available for review, 14 ASA users were identified. ASA users demonstrated increased OS (p = 0.03) and DMFS (p = 0.02), with 5-year OS and DMFS of 92% (p = 0.01) and 85% (p = 0.01) compared to 51% and 43%, respectively, for non-ASA users. In univariate analysis, pT stage, pN stage, and ASA use were significantly correlated (p < 0.05) with OS and DFS. On multivariable analysis, ASA use (hazard ratio [HR], 0.11; 95% confidence interval [CI], 0.01–0.8) and lymph node stage (HR, 5.9; 95% CI, 1.4–25.9) remained significant for OS and DFS ASA use (HR, 0.13; 95% CI, 0.03–0.56) and lymph node stage (HR, 5.6; 95% CI, 1.9–16.4). Conclusion: ASA use during remission was associated with significantly improved OS and DMFS in patients with IBC. These results suggest that ASA may provide survival benefits to patients with IBC. Prospective clinical trials of ASA use in patients with high-risk IBC in remission should be considered.

#Aspirin #Inflammatory Breast Neoplasms #Neoplasm Metastasis #Survival

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

Christopher Johns

소속기관 Department of Radiation Oncology University of Texas Southwestern Medical Center Dallas USA.